Ecopipam
- Generic Name
- Ecopipam
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20ClNO
- CAS Number
- 112108-01-7
- Unique Ingredient Identifier
- 0X748O646K
- Background
Ecopipam has been used in trials studying the treatment of Tourette's Syndrome, Lesch-Nyhan Disease, Pathological Gambling, and Self-injurious Behavior.
- Associated Conditions
- -
- Associated Therapies
- -
Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06194864
- Locations
- 🇨🇦
Syneos Health Clinic Inc., Québec, Quebec, Canada
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06021522
- Locations
- 🇮🇹
Ospedale Pediatrico Bambino Ges, Roma, RM, Italy
🇪🇸Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
- First Posted Date
- 2022-04-19
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT05334108
- Locations
- 🇺🇸
ICON Early Phase Services, San Antonio, Texas, United States
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
- Conditions
- Interventions
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT04492956
- Locations
- 🇺🇸
Clinical Neuroscience Solutions Inc, Memphis, Tennessee, United States
🇺🇸UC Riverside, Riverside, California, United States
🇺🇸Michigan State University, East Lansing, Michigan, United States
Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04114539
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The University of Chicago Hospitals, Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT04007991
- Locations
- 🇺🇸
Harmonex Neuroscience Research, Dothan, Alabama, United States
🇺🇸Advanced Research Center Inc., Anaheim, California, United States
🇺🇸Clinical Research Center of NJ, Voorhees, New Jersey, United States
Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- William Ondo, MD
- Target Recruit Count
- 10
- Registration Number
- NCT03218969
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years
- First Posted Date
- 2014-04-03
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02102698
- Locations
- 🇺🇸
University of South Florida/Rothman Center for Neuropsychiatry, Saint Petersburg, Florida, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Emory University School Of Medicine, Atlanta, Georgia, United States
Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease
- Conditions
- Interventions
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01751802
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
🇺🇸H.J. Jinnah, Atlanta, Georgia, United States
Ecopipam Treatment of Tourette Syndrome
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2015-09-29
- Lead Sponsor
- Psyadon Pharma
- Target Recruit Count
- 18
- Registration Number
- NCT01244633
- Locations
- 🇺🇸
Atlantic Neuroscience Institute Overlook Hospital, Summit, New Jersey, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸North Shore Hospital, Manhasset, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.